Gilead Sciences and Arcellx
Type: Acquisition
Buyer: Gilead Sciences
Seller: Arcellx
Focus: Anitocabtagene autoleucel (anito-cel)
Deal value: $7.8 billion
Financial impact: Gilead Sciences, Inc.’s up to $7.8 billion acquisition of Arcellx, Inc. strengthens its oncology and CAR-T portfolio, with potential long-term earnings accretion from anito-cel, though it involves significant upfront costs and execution risk.
Gilead Sciences, Inc. has agreed to acquire Arcellx, Inc. for $115 per share in cash plus a $5 contingent value right, valuing the company at approximately $7.8 billion. Arcellx specializes in innovative immunotherapies for cancer and other serious diseases.
The acquisition builds on Gilead’s existing collaboration through Kite Pharma to develop anitocabtagene autoleucel (anito-cel), a BCMA-targeted CAR-T therapy for multiple myeloma, addressing ongoing unmet needs as many patients relapse and face limited treatment options.
Anitocabtagene autoleucel (anito-cel)
Anitocabtagene autoleucel (also known as CART-ddBCMA) is a BCMA-targeted CAR-T therapy developed by Arcellx, Inc. for multiple myeloma and myasthenia gravis, using the LentiVector® platform licensed from Oxford BioMedica.
The therapy employs ARC-T cells that are activated and directed toward cancer cells via a soluble protein antigen-receptor X-linker (sparX). By replacing the conventional CAR binding domain with a proprietary TAG-specific domain, the system enhances targeting precision. The ARC-T and sparX complex enables controlled tumor cell killing.
The therapy is awaiting U.S. approval for multiple myeloma, with ongoing clinical development in myasthenia gravis. SparX proteins are produced using Primrose Bio’s Expression Technology® platform and can be designed as mono-, bi-, or bispecific constructs to address tumor heterogeneity.
Eleven years’ market revenue of Gilead Sciences
Gilead Sciences, Inc. expected slower growth in 2015 due to pricing pressure, competition, and weaker prescription growth, despite strong demand for its HIV and hepatitis C drugs. Although short-term growth moderated, the company maintained a strong cash position, limited patent risk, and a leading HIV portfolio.
Revenue declined from $26.1 billion in 2017 to $22.1 billion in 2018, mainly due to falling hepatitis C sales, though HIV products continued to grow. From 2019 onward, performance stabilized and improved, reaching $24.7 billion in 2020 and $27.3 billion in 2021, driven largely by COVID-19 treatment Veklury and expanding oncology sales. Revenue remained around $27 billion in 2022–2023 as HIV and oncology growth offset declining Veklury sales.
Eleven years market revenue of Gilead Sciences (2015-2025)
Fig 6: Market revenue of Gilead Sciences
Growth resumed in 2024 and 2025, with revenue rising to $28.8 billion and $29.4 billion, respectively, supported by strong HIV sales—particularly Biktarvy—and continued oncology momentum, despite lower COVID-related revenue.
Market Impact of This Partnership
The announcement triggered a sharp surge in Arcellx’s share price, which jumped nearly 78 % on the news as the offer includes a significant premium over the prior market price. Meanwhile, Gilead’s own shares were relatively flat or slightly weaker, reflecting investor focus on the long-term strategic rationale rather than immediate earnings impact.
Analysts see the deal as a strategic expansion into oncology and CAR-T cell therapy, signalling confidence in Arcellx’s lead asset anito-cel and reinforcing Gilead’s pipeline diversification beyond traditional antiviral products. The acquisition is expected to be earnings accretive by around 2028, assuming regulatory approval and commercial success of the CAR-T therapy, and has influenced analyst ratings and price targets on Gilead stock.
Overall, the market reaction reflects positive sentiment for Arcellx shareholders, validation of the underlying therapy’s potential, and a broader trend of consolidation in the cell therapy sector as big pharma seeks new growth drivers.
“Gilead’s $7.8B acquisition of Arcellx drove a sharp surge in Arcellx shares and reinforced Gilead’s strategic push into oncology and CAR-T therapies.”